Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection

NCT02428400 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT02428400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02428400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection
Lead sponsor
Transgene
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2015
Completion date
November 30, 2018
Enrollment
48 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b